Search

Your search keyword '"Wan-Lung Chuang"' showing total 38 results
Start Over Author "Wan-Lung Chuang" Publisher elsevier bv
38 results on '"Wan-Lung Chuang"'

1. Use of noninvasive biomarkers to assess fibrosis regression in cirrhotic patients during nucleos(t)ide therapy

Author

Elena Nurmukhametova, Wan-Lung Chuang, Patrick Marcellin, Namiki Izumi, Stephen D. Ryder, John F. Flaherty, Mani Subramanian, Thien Nguyen, Anuj Gaggar, R. Balabanska, Calvin Q. Pan, J. Yang, Lanjia Lin, A. Duseja, and P. Angus

Subjects
medicine.medical_specialty, Hepatology, business.industry, Fibrosis, Internal medicine, medicine, business, medicine.disease, Gastroenterology, Regression, Noninvasive biomarkers
Published
2018
Full Text
View/download PDF

2. Tumor Necrosis Factor-α 308.2 Polymorphism Is Associated with Advanced Hepatic Fibrosis and Higher Risk for Hepatocellular Carcinoma

Author

Jen-Sing Jeng, Mei-Shang Ho, Lee-Yea Chuang, Jung-Fa Tsai, Wan-Lung Chuang, Min-Yuh Hsieh, Shin-Chern Chen, Liang-Yen Wang, Ming-Lung Yu, Zu-Yau Lin, Jan-Gowth Chang, and Chia-Yen Dai

Subjects
Hepatitis B virus, Single-nucleotide polymorphism, Cancer Research, HBsAg, Cirrhosis, Hepatitis C virus, hepatocellular carcinoma, Biology, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, medicine.disease_cause, lcsh:RC254-282, risk factor, Hepatocellular carcinoma, Immunology, medicine, hepatic fibrosis, Allele, tumor necrosis factor-α, Hepatic fibrosis
Abstract

BACKGROUND/AIMS : Host genetic factor and hepatic fibrosis may predispose to risk for hepatocellular carcinoma (HCC). This study aimed to assess the association between tumor necrosis factor (TNF) α polymorphism and hepatic fibrosis, and risk for HCC. METHODS : One hundred eight pairs of gender-matched and age-matched patients with HCC and unrelated healthy controls were genotyped for TNF308.2 and TNF238.2 alleles with polymerase chain reaction and direct sequencing. RESULTS : The frequency of TNF308.1/TNF308.2 genotype in cases was higher than that in controls [odds ratio (OR) = 4.37]. Multivariate analysis indicated that TNF308.2 allele (OR = 3.23), hepatitis B surface antigen (OR = 17.17), and antibodies to hepatitis C virus (OR = 45.52) were independent risk factors for HCC. Surrogate markers for significant fibrosis implied that cases with the TNF308.2 allele have more advanced liver fibrosis. Moreover, multivariate analysis indicated that cirrhosis with Child-Pugh grade C, low serum albumin, and low platelet count were independent risk factors for carrying the TNF308.2 allele. CONCLUSIONS : TNF308.2 allele carriage and chronic hepatitis B virus/hepatitis C virus infection are independent risk factors for HCC. Carriage of the TNF308.2 allele correlates with disease severity and hepatic fibrosis, which may contribute to a higher risk for HCC.

Published
2007
Full Text
View/download PDF

3. A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96

Author

Mustafa Kemal Çelen, E.J. Gane, Wan-Lung Chuang, Maurizia Rossana Brunetto, G.M. Subramanian, John F. Flaherty, Hung Chan, M. Osipenko, Sung-Ku Ahn, Young-Suk Lim, Calvin Q. Pan, Wai-Kay Seto, Audrey H. Lau, Vithika Suri, Namiki Izumi, Huy N. Trinh, Anuj Gaggar, Neeru Bhardwaj, H.L.A. Janssen, Akash Shukla, M. Buti, Kyungpil Kim, and Patrick Marcellin

Subjects
medicine.medical_specialty, Hepatology, Tenofovir, business.industry, Phases of clinical research, Tenofovir alafenamide, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Hbeag negative, Chronic hepatitis, Internal medicine, medicine, 030211 gastroenterology & hepatology, In patient, 030212 general & internal medicine, business, medicine.drug
Published
2017
Full Text
View/download PDF

4. Smaller decreases in bone mineral density in chronic hepatitis B patients receiving tenofovir alafenamide compared with tenofovir disoproxil fumarate over 96 weeks

Author

Anuj Gaggar, Seng Gee Lim, Scott Fung, Wan-Lung Chuang, Maciej Jabłkowski, Vithika Suri, Kyungpil Kim, Shuhei Nishiguchi, Mustafa Kemal Çelen, E.M. Erne, H.L. Chan, G.M. Subramanian, Audrey H. Lau, Wai-Kay Seto, Won Young Tak, John F. Flaherty, and V. Morozov

Subjects
Bone mineral, medicine.medical_specialty, Hepatology, Tenofovir, business.industry, Virology, Gastroenterology, Tenofovir alafenamide, 03 medical and health sciences, 0302 clinical medicine, Chronic hepatitis, 030220 oncology & carcinogenesis, Internal medicine, Medicine, 030211 gastroenterology & hepatology, business, medicine.drug
Published
2017
Full Text
View/download PDF

5. Ledipasvir/sofosbuvir for 12 weeks is safe and effective in patients with chronic hepatitis C and hepatitis B coinfection: A phase 3 study in Taiwan

Author

Wan-Lung Chuang, Jenny C. Yang, J.-J. Chen, Pei-Jer Chen, Chi-Jen Chu, C. Chen, Gregory Camus, You-Chun Hsu, Tsung-Hui Hu, Rong-Nan Chien, Horng-Yuan Wang, John G. McHutchison, Fangqiu Zhang, Chun-Jen Liu, I-Shyan Sheen, D.M. Brainard, Cheng Yuan Peng, Kuo-Chih Tseng, Benedetta Massetto, Ting-Tsung Chang, and Gin-Ho Lo

Subjects
Hepatology, business.industry, Phases of clinical research, Hepatitis B, medicine.disease, Virology, 03 medical and health sciences, 0302 clinical medicine, Chronic hepatitis, Coinfection, medicine, LEDIPASVIR/SOFOSBUVIR, 030211 gastroenterology & hepatology, In patient, 030212 general & internal medicine, business
Published
2017
Full Text
View/download PDF

6. IL-6/STAT3 Pathway Up-Regulate MIR-125B Expression in Hepatitis C Virus Infection

Author

M.-L. Yu, Jee-Fu Huang, Wan-Lung Chuang, Chia-Yen Dai, Chung Feng Huang, and Ming-Lun Yeh

Subjects
Hepatology, Hepatitis B virus DNA polymerase, Hepatitis C virus, Viral transformation, 02 engineering and technology, Biology, 010402 general chemistry, 021001 nanoscience & nanotechnology, medicine.disease_cause, 01 natural sciences, Virology, Hepatitis B virus PRE beta, 0104 chemical sciences, Il 6 stat3, medicine, 0210 nano-technology, Mir 125b
Published
2016
Full Text
View/download PDF

7. A Phase 3 Study of Tenofovir Alafenamide Compared with Tenofovir Disoproxil Fumarate in Patients with Hbeag-Negative, Chronic Hepatitis B: Week 48 Efficacy and Safety Results

Author

John G. McHutchison, R. Mehta, Phillip Dinh, Young-Suk Lim, John F. Flaherty, Subrat K. Acharya, T. Stepanova, Benedetta Massetto, Patrick Marcellin, Calvin Q. Pan, Aric J. Hui, Wai-Kay Seto, Andrea L. Cathcart, Maurizia Rossana Brunetto, E.J. Gane, Hung Chan, M. Buti, H.L.A. Janssen, G.M. Subramanian, Wan-Lung Chuang, and Namiki Izumi

Subjects
medicine.medical_specialty, Hepatology, Tenofovir, business.industry, Phases of clinical research, University hospital, Tenofovir alafenamide, 03 medical and health sciences, 0302 clinical medicine, Hbeag negative, Chronic hepatitis, Family medicine, Medicine, 030211 gastroenterology & hepatology, In patient, 030212 general & internal medicine, business, China, medicine.drug
Abstract

A PHASE 3 STUDY OF TENOFOVIR ALAFENAMIDE COMPARED WITH TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HBEAGNEGATIVE, CHRONIC HEPATITIS B: WEEK 48 EFFICACYAND SAFETY RESULTS M. Buti1, E. Gane2, W.K. Seto3, H.L.Y. Chan4, W.-L. Chuang5, T. Stepanova6, A.J. Hui7, Y.-S. Lim8, R. Mehta9, H.L.A. Janssen10,11, S.K. Acharya12, J.F. Flaherty13, B. Massetto13, A. Cathcart13, P. Dinh13, G.M. Subramanian13, J.G. McHutchison13, C. Pan14, M. Brunetto15, N. Izumi16, P. Marcellin17. 1Hospital General Universitari Vall d’Hebron, Barcelona, Spain; 2Auckland Clinical Studies, Auckland, New Zealand; 3Queen Mary Hospital; 4The Chinese University of Hong Kong, Hong Kong, Hong Kong, China; 5Kaoshing Medical University Hospital, Kaoshing, Taiwan; 6Modern Medicine Clinic, Moscow, Russia; 7Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong, China; 8Asan Medical Center, Seoul, South Korea; 9Nirmal Hospital Private Limited, Surat, India; 10Toronto Western Hospital, Toronto, Canada; 11Erasmus Medical Center, Rotterdam, Netherlands; 12All India Institute of Medical Sciences, New Delhi, India; 13Gilead Sciences, Foster City; 14New Discovery, LLC, Flushing, United States; 15University Hospital of Pisa, Pisa, Italy; 16Musashino Red Cross Hospital, Tokyo, Japan; 17Hopital Beaujon, Clichy, France E-mail: John.Flaherty@gilead.com

Published
2016
Full Text
View/download PDF

9. HBsAg Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2A in Chronic Hepatitis B: Long-Term Results of a Global Randomized Controlled Trial

Author

G. Mani Subramanian, Jörg Petersen, Won Young Tak, Fehmi Tabak, Maria Buti, Patrick Marcellin, Phillip Dinh, Amy Corsa, Eduardo B. Martins, Hoi-Yun Chan, Magdy Elkhashab, R. Mehta, Wan-Lung Chuang, G. B. Gaeta, George V. Papatheodoridis, Robert Flisiak, F.A. Caruntu, Leland J. Yee, Sung-Ku Ahn, and Xiaoli Ma

Subjects
0301 basic medicine, medicine.medical_specialty, HBsAg, Hepatology, Tenofovir, business.industry, Long term results, Gastroenterology, law.invention, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Randomized controlled trial, Chronic hepatitis, law, Internal medicine, medicine, 030211 gastroenterology & hepatology, business, medicine.drug, Peginterferon alfa-2a
Published
2016
Full Text
View/download PDF

10. P0857 : 98% SVR12 in Korean and Taiwanese patients with chronic genotype 1 HCV infection receiving 12 weeks of ledipasvir/sofosbuvir: Results from an international, multicenter phase 3 study

Author

Sang Hoon Ahn, Young-Suk Lim, Ting-Tsung Chang, B. Gao, Rong-Nan Chien, Chi-Jen Chu, Wan-Lung Chuang, Jia-Horng Kao, Sook-Hyang Jeong, S.J. Knox, Phillip S. Pang, Kwang Hyub Han, Youn Jae Lee, J.G. McHutchison, Cheng Yuan Peng, Hongmei Mo, Seung Woon Paik, and Jenny C. Yang

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Genotype, Phases of clinical research, Medicine, LEDIPASVIR/SOFOSBUVIR, business, Intensive care medicine
Published
2015
Full Text
View/download PDF

11. O117 : Predictors of clinical response: Results from a large, randomized controlled study with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB)

Author

Lanjia Lin, Magdy Elkhashab, Scott Fung, Simone I. Strasser, J.G. McHutchinson, G.M. Subramanian, Wan-Lung Chuang, Chuan-Mo Lee, Georgios Papatheodoridis, Kosh Agarwal, Graham R. Foster, Jörg Petersen, Aric J. Hui, Didier Samuel, Won Young Tak, Ramazan Idilman, M. Buti, Seng Gee Lim, F.A. Caruntu, Robert Flisiak, G. B. Gaeta, H.L. Chan, L. Morano, R. Mehta, Fehmi Tabak, Eduardo B. Martins, Phillip Dinh, Patrick Marcellin, Prista Charuworn, Sung-Ku Ahn, and Xiaoli Ma

Subjects
medicine.medical_specialty, Hepatology, Tenofovir, business.industry, Gastroenterology, law.invention, Randomized controlled trial, Chronic hepatitis, law, Internal medicine, PEG ratio, medicine, business, medicine.drug, Peginterferon alfa-2a
Published
2015
Full Text
View/download PDF

12. Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: preliminary results from 2 phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B

Author

H.L. Chan, H.L.A. Janssen, John F. Flaherty, Vithika Suri, Scott Fung, E.J. Gane, Lanjia Lin, Wai-Kay Seto, M. Buti, Anuj Gaggar, Kosh Agarwal, G.M. Subramanian, and Wan-Lung Chuang

Subjects
HBEAG POSITIVE, medicine.medical_specialty, Hepatology, Tenofovir, business.industry, Tenofovir alafenamide, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Chronic hepatitis, Hbeag negative, 030220 oncology & carcinogenesis, Internal medicine, Medicine, 030211 gastroenterology & hepatology, business, medicine.drug
Published
2017
Full Text
View/download PDF

13. Continued improvement in renal laboratory parameters in CHB patients treated with tenofovir alfenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) over 96 weeks

Author

Audrey H. Lau, Hie-Won Hann, G.M. Subramanian, H. Yatsuhashi, Anuj Gaggar, F.A. Caruntu, Young-Suk Lim, Aric J. Hui, Vithika Suri, John F. Flaherty, J.S. Hwang, Wan-Lung Chuang, Kosh Agarwal, Florence Wong, and Shuyuan Mo

Subjects
03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, Hepatology, Tenofovir, business.industry, 030220 oncology & carcinogenesis, Urology, medicine, 030211 gastroenterology & hepatology, business, medicine.drug
Published
2017
Full Text
View/download PDF

14. Regional differences in the presentation and management of patients with hepatocellular carcinoma by liver disease etiology

Author

Pei-Chien Tsai, Ming-Lung Yu, Myron Schwartz, Y.-L. Chen, N.G. Kim, Jee-Fu Huang, Young-Min Lim, H.Y. Lee, Ming-Lun Yeh, L. Roberts, Dae Won Jun, H.-I Yang, Mindie H. Nguyen, M. Jun, Waqar Khalid Saeed, Chia-Yen Dai, Wan-Lung Chuang, J.D. Yang, P. Nguyen, and Jennifer Leong

Subjects
Liver disease, Pathology, medicine.medical_specialty, Hepatology, business.industry, Hepatocellular carcinoma, Etiology, Medicine, Presentation (obstetrics), business, medicine.disease, Regional differences
Published
2017
Full Text
View/download PDF

15. HBeAg Seroconversion Rates after Five Years of Follow-Up in Patients Treated with Peginterferon Alfa-2a (40kd) in Neptune: Final Results of the Son of Neptune Long-Term Follow-Up Study

Author

Joseph J.Y. Sung, Jidong Jia, E.J. Gane, Teerha Piratvisuth, Diethelm Messinger, Hung Chan, Qing Xie, Kwang Hyub Han, Cynthia Wat, X.-P. Chen, Tawesak Tanwandee, Georgios Bakalos, Wan-Lung Chuang, Lei Chen, Deming Tan, and Yun-Fan Liaw

Subjects
Pediatrics, medicine.medical_specialty, Hepatology, business.industry, Long term follow up, Hbeag seroconversion, Immunology, Medicine, In patient, business, Peginterferon alfa-2a, medicine.drug
Published
2016
Full Text
View/download PDF

16. P0809 : 98% SVR12 in Korean And Taiwanese patients with chronic genotype 2 HCV infection receiving 12 weeks of sofosbuvir plus ribavirin: Results from an international, multicenter phase 3 study

Author

Seung-Woon Paik, Youn Jae Lee, Chi-Jen Chu, Sook-Hyang Jeong, John G. McHutchison, Jenny C. Yang, Rong-Nan Chien, Hongmei Mo, Young-Suk Lim, Wan-Lung Chuang, Cheng Yuan Peng, Kwang Hyub Han, Sang Hoon Ahn, Ting-Tsung Chang, D.M. Brainard, Jia-Horng Kao, Steven J. Knox, and L. Han

Subjects
medicine.medical_specialty, Hepatology, Sofosbuvir, business.industry, Ribavirin, Phases of clinical research, Gastroenterology, chemistry.chemical_compound, chemistry, Internal medicine, Genotype, medicine, business, medicine.drug
Published
2015
Full Text
View/download PDF

19. 1406 ALISPORIVIR (ALV) PLUS PEG-INTERFERON/RIBAVIRIN (PR) IN HCV G1 TREATMENT-EXPERIENCED PATIENTS ACHIEVES PRIMARY ENDPOINT WITH SUPERIOR EFFICACY AT TREATMENT WEEK 12 COMPARED TO RETREATMENT WITH PR

Author

Claudio Avila, Petre Iacob Calistru, Maria Buti, Alfredo Alberti, Robert Flisiak, Y. Gong, Wan-Lung Chuang, Giuseppe Mazzella, Andrzej Horban, Jia-Horng Kao, G. Davis, and Tobias Goeser

Subjects
medicine.medical_specialty, Alisporivir, Hepatology, business.industry, Ribavirin, Decompensated cirrhosis, Virology, Gastroenterology, Treatment experienced, Peg interferon, chemistry.chemical_compound, chemistry, Internal medicine, Clinical endpoint, Medicine, business
Abstract

Conclusions: ACLF is a distinct syndrome characterized by extrahepatic organ failure(s) leading to a high short-term mortality, which depends on the number of failing organs as defined by the CLIF-SOFA score. It not only develops in previously decompensated, but also in compensated or early decompensated cirrhosis. ACLF is related to systemic inflammatory reaction due to bacterial infection, alcoholic injury or other as-yet unidentified mechanisms.

Published
2012
Full Text
View/download PDF

20. 1171 MICRORNA EXPRESSION PROFILING IN PERIPHERAL BLOOD MONONUCLEAR CELLS IDENTIFIES TWO MIRNAS ASSOCIATED WITH TREATMENT RESPONSE TO PEGINTERFERON-RIBAVIRIN IN CHRONIC HEPATITIS C VIRUS PATIENTS

Author

Chia-Yen Dai, E. Hsi, Jee-Fu Huang, Wan-Lung Chuang, Suh-Hang Hank Juo, M.-L. Yu, and Chung Feng Huang

Subjects
Gene expression profiling, Treatment response, Hepatology, Chronic hepatitis, business.industry, microRNA, Immunology, Medicine, PEGINTERFERON/RIBAVIRIN, business, Peripheral blood mononuclear cell, Virus
Published
2012
Full Text
View/download PDF

21. The Value of Ultrasound-Guided Procedures in the Treatment of Advanced Hepatocellular Carcinoma: Presented with a Case of Extra-Long Survival

Author

Ding-Kwo Wu, Wan-Lung Chuang, and S.-C. Chen

Subjects
medicine.medical_specialty, Acoustics and Ultrasonics, Radiological and Ultrasound Technology, business.industry, General surgery, Biophysics, medicine.disease, Ultrasound guided, Hepatocellular carcinoma, medicine, Radiology, Nuclear Medicine and imaging, Radiology, business, Value (mathematics)
Published
2011
Full Text
View/download PDF

22. 424 RESPIRATORY ALTERATIONS IN GENOTYPE 2/3 CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGYLATED INTERFERON OR ALBINTERFERON-ALFA-2B PLUS RIBAVIRIN IN A RANDOMIZED STUDY

Author

Y. Yin, Wan-Lung Chuang, Tawesak Tanwandee, Jacob George, Ajit Sood, Kevin K. Brown, Graham R. Foster, Jens Rasenack, Martin Weltman, Wattana Sukeepaisarnjaroen, Piyawat Komolmit, Satawat Thongsawat, Robert Flisiak, G. Feutren, and Ricard Solà

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Genetic enhancement, Ribavirin, Pirfenidone, medicine.disease, Gastroenterology, law.invention, chemistry.chemical_compound, chemistry, Randomized controlled trial, law, Pegylated interferon, Fibrosis, Internal medicine, medicine, business, Albinterferon Alfa-2b, medicine.drug
Abstract

423 TREATMENT WITH PIRFENIDONE PRODUCES AN IMPORTANT REDUCTION IN NECROINFLAMMATION SCORE, FIBROSIS INDEX AND INCREASED GENE EXPRESSION OF CB2 IN PATIENTS WITH LIVER CIRRHOSIS L. Flores Contreras, A. Sandoval-Rodriguez, S. Lucano-Landeros, I. Arellano-Olivera, J. Armendariz-Borunda. Molecular Biology, Institute of Molecular Biology and Gene Therapy, CUCS, Universidad de Guadalajara, O.P.D. Hospital Civil ‘Juan I Menchaca’, Guadalajara, Mexico E-mail: lucia_floresc1@yahoo.com.mx

Published
2011
Full Text
View/download PDF

25. 13 TELBIVUDINE (LDT) PLUS PEG-INTERFERON (PEGIFN) IN HBEAG-POSITIVE CHRONIC HEPATITIS B – VERY POTENT ANTIVIRAL EFFICACY BUT RISK OF PERIPHERAL NEUROPATHY (PN)

Author

E.J. Gane, Nikolai V. Naoumov, Karsten Wursthorn, Claudio Avila, Patrick Marcellin, George K. K. Lau, Hugo Fainboim, M.P. Manns, Wan-Lung Chuang, and Cheng Yuan Peng

Subjects
HBEAG POSITIVE, medicine.medical_specialty, Hepatology, business.industry, medicine.disease, Gastroenterology, Virology, Peg interferon, Peripheral neuropathy, Chronic hepatitis, Telbivudine, Internal medicine, Medicine, business, medicine.drug
Published
2010
Full Text
View/download PDF

26. 1053 ASSOCIATION BETWEEN DIABETES MELLITUS, HEPATIC STEATOSIS AND FIBROSIS IN CHRONIC HEPATITIS C PATIENTS IN TAIWAN

Author

Chia-Yen Dai, N.-J. Hou, Jee-Fu Huang, Wan-Lung Chuang, S.-C. Chen, Zu-Yau Lin, L.-Y. Wang, Ming Yen Hsieh, and M.-L. Yu

Subjects
education.field_of_study, medicine.medical_specialty, Hepatology, business.industry, Proportional hazards model, Hepatitis C virus, Population, medicine.disease_cause, medicine.disease, Confidence interval, Serology, Relative risk, Internal medicine, Diabetes mellitus, medicine, Steatosis, business, education
Abstract

Background: Cerebrovascular disease is one of the leading causes of death worldwide. Hepatitis C virus (HCV) infection, a well-accepted causal agent for liver-related diseases, has been reported to increase the risk for atherothrombosis. However, the association between HCV infection and cerebrovascular diseases remains inconclusive and the dose-response relationship between serum HCVRNA levels and cerebrovascular death has never been elucidated. Methods: This study enrolled 23,665 residents aged between 30–65 years in community during 1991–1992. They were personally interviewed using structured questionnaires and provided blood samples for various serological and biochemical testing at study entry. Those who were seropositive for antibodies against HCV (anti-HCV) were examined for serum HCVRNA levels. HCV genotypes were determined in participants who had detectable serum HCVRNA. Cerebrovascular deaths of participants during follow-up were ascertained by computerized linkage with National Death Certification profiles from 1991 to 2007 (ICD-9: 430–438). Person-years at risk were calculated for each person as time from enrollment date to either the date of death, or to the end of 2007, whichever came first. Cox proportional hazards models were used to estimate relative risks and 95% confidence intervals for magnitude of HCV after adjustment of other risk factors. Results: There were 240 cerebrovascular deaths with 361,171 person-years of follow-up, giving a mortality of 66.5 per 100,000 person-years in this population. The cumulative risks for cerebrovascular death were 1.0% and 2.7% for anti-HCV seronegatives and anti-HCV seropositives (p < 0.001). Participants seropositive for anti-HCV had increased risk of cerebrovascular death, with a multivariate-adjusted relative risk (95% confidence interval) of 2.27 (1.56–3.30). Elevated serum HCVRNA levels increased the risk for cerebrovascular death with dose-response trend (p < 0.001). The adjusted relative risks were 1.52 (0.67– 3.44), 1.73 (0.43–6.98), 2.31 (1.25–4.25), and 3.45 (1.76– 6.75) in corresponding to participants with serum HCVRNA level

Published
2010
Full Text
View/download PDF

27. 1421 ALISPORIVIR (ALV) PLUS PEGINTERFERON/RIBAVIRIN (PR) ACHIEVES HIGH SVR12 RATES AMONG NULL RESPONDERS, IL28BCT/TT AND CIRRHOTIC HCVG1 PATIENTS (FUNDAMENTAL STUDY INTERIM ANALYSIS)

Author

Anca Streinu-Cercel, J. Wang, Wan-Lung Chuang, Fehmi Tabak, Maria Buti, Alfredo Alberti, Jia-Horng Kao, Jens Rasenack, G. Davis, Claudio Avila, Robert Flisiak, Tobias Goeser, Carol Stanciu, R. Orsenigo, and G. Hofstetter

Subjects
Oncology, medicine.medical_specialty, Fundamental study, Alisporivir, Hepatology, business.industry, Internal medicine, Null (mathematics), medicine, PEGINTERFERON/RIBAVIRIN, Interim analysis, business, Virology
Published
2013
Full Text
View/download PDF

28. 1405 ALISPORIVIR PLUS RIBAVIRIN IS HIGHLY EFFECTIVE AS INTERFERON-FREE OR INTERFERON-ADD-ON REGIMEN IN PREVIOUSLY UNTREATED HCV-GT2 OR GT3 PATIENTS: SVR12 RESULTS FROM VITAL-1 PHASE 2B STUDY

Author

H. Wedemeyer, Cheng Yuan Peng, Jean-Michel Pawlotsky, Shiv Kumar Sarin, Jens Rasenack, W.M. Zhang, Teerha Piratvisuth, Robert Flisiak, Graham R. Foster, Wan-Lung Chuang, and Nikolai V. Naoumov

Subjects
Alisporivir, chemistry.chemical_compound, Regimen, Hepatology, chemistry, Interferon, business.industry, Ribavirin, Interferon free, medicine, business, Virology, medicine.drug
Published
2012
Full Text
View/download PDF

30. 69 NEPTUNE STUDY: ON-TREATMENT HBSAG LEVEL ANALYSIS CONFIRMS PREDICTION OF RESPONSE OBSERVED IN PHASE 3 STUDY OF PEGINTERFERON ALFA-2A IN HBEAG-POSITIVE PATIENTS

Author

Tawesak Tanwandee, E.J. Gane, Wan-Lung Chuang, Yun-Fan Liaw, Cynthia Wat, Teerha Piratvisuth, Patrick Marcellin, Eduardo B. Martins, Jidong Jia, Kwang Hyub Han, and H.L. Chan

Subjects
HBEAG POSITIVE, HBsAg, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, medicine, Phases of clinical research, business, Virology, Gastroenterology, Peginterferon alfa-2a, medicine.drug
Published
2011
Full Text
View/download PDF

31. 53 RELATION BETWEEN SUSTAINED VIROLOGIC RESPONSE AND INSULIN RESISTANCE IN PATIENTS WITH GENOTYPE 1 OR 2/3 CHRONIC HEPATITIS C

Author

Maciej Jabłkowski, M. Diago, Alexander J. Thompson, G.M. Subramanian, Petr Urbánek, John G. McHutchison, Peter Ferenci, Yoav Lurie, Wan-Lung Chuang, Dieter Häussinger, Graham R. Foster, Carol Stanciu, and S. Pianko

Subjects
medicine.medical_specialty, Insulin resistance, Hepatology, Chronic hepatitis, business.industry, Internal medicine, Virologic response, Genotype, medicine, In patient, medicine.disease, business, Gastroenterology
Published
2010
Full Text
View/download PDF

32. 1042 EFFICACY AND SAFETY RESULTS OF ALBINTERFERON ALFA-2B IN COMBINATION WITH RIBAVIRIN IN INTERFERON-ALFA TREATMENT NAIVE PATIENTS WITH GENOTYPE 2 OR 3 CHRONIC HEPATITIS C

Author

John G. McHutchison, Patrick W. Cronin, Robert Flisiak, Erik Pulkstenis, Maribel Rodriguez-Torres, Wan-Lung Chuang, Kushang V. Patel, G.M. Subramanian, David R. Nelson, Vincent G. Bain, Eric Lawitz, and Yves Benhamou

Subjects
medicine.medical_specialty, Hepatology, business.industry, Ribavirin, Gastroenterology, Therapy naive, chemistry.chemical_compound, chemistry, Chronic hepatitis, Internal medicine, Genotype, medicine, business, Albinterferon Alfa-2b, Interferon alfa, medicine.drug
Published
2009
Full Text
View/download PDF

33. 617 EFFICACY AND SAFETY OF PEGYLATED INTERFERON- ALPHA PLUS RIBAVIRIN COMBINATION THERAPY IN OLD AGE CHRONIC HEPATITIS C PATIENTS

Author

M.-L. Yu, Jee-Fu Huang, Wan-Lung Chuang, Chia-Yen Dai, and Chung Feng Huang

Subjects
medicine.medical_specialty, Hepatology, Combination therapy, business.industry, Ribavirin, Alpha (ethology), Gastroenterology, chemistry.chemical_compound, Chronic hepatitis, chemistry, Pegylated interferon, Internal medicine, medicine, business, medicine.drug
Published
2009
Full Text
View/download PDF

34. 621 A simple non-invasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy

Author

Wen-Yu Chang, M.-L. Yu, Chia-Yen Dai, and Wan-Lung Chuang

Subjects
medicine.medical_specialty, Index (economics), Hepatology, business.industry, Non invasive, Outcome (game theory), Gastroenterology, Virology, Term (time), Chronic hepatitis, Interferon, Internal medicine, Medicine, business, Simple (philosophy), medicine.drug
Published
2006
Full Text
View/download PDF

35. The role of real-time ultrasound in evaluating the effect of pure ethanol injection therapy and acetic acid injection therapy in treating small hepatocellular carcinoma

Author

Min-Yuh Hsieh, Zu-Yau Lin, L.-Y. Wang, S.-C. Chen, Cheng Hou, Wan-Lung Chuang, and Wen-Yu Chang

Subjects
medicine.medical_specialty, Acoustics and Ultrasonics, Radiological and Ultrasound Technology, business.industry, Biophysics, Injection therapy, Real time ultrasound, Ethanol Injection, medicine.disease, Gastroenterology, Acetic acid, chemistry.chemical_compound, chemistry, Hepatocellular carcinoma, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, business
Published
2003
Full Text
View/download PDF

36. The preliminary report of characteristics of abdominal ultrasound in Dengue fever patients

Author

J.-F. Tsai, Min-Yuh Hsieh, Wan-Lung Chuang, Zu-Yau Lin, S.-C. Chen, Chaw-Chi Chiu, L.-Y. Wang, and Wen-Yu Chang

Subjects
medicine.medical_specialty, Acoustics and Ultrasonics, Radiological and Ultrasound Technology, business.industry, Preliminary report, Abdominal ultrasound, Biophysics, Medicine, Radiology, Nuclear Medicine and imaging, Radiology, business, medicine.disease, Dengue fever
Published
2003
Full Text
View/download PDF

37. Preventive effects of antiviral therapy on progression of chronic hepatitis C virus infection to liver cirrhosis and hepatocellular carcinoma in Taiwan

Author

S.-C. Chen, Li-Po Lee, Ming Yen Hsieh, Wan-Lung Chuang, Wen-Yu Chang, L.-Y. Wang, M.-L. Yu, Chia-Yen Dai, and Zu-Yau Lin

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, Chronic hepatitis, business.industry, Internal medicine, Hepatocellular carcinoma, medicine, Antiviral therapy, medicine.disease, business, Gastroenterology, Virus
Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results